Meet the 2025 FAST Spring cohort—twelve innovative life sciences startups developing impactful solutions. These companies will spend the next several weeks working with our curated network of advisors to develop a compelling commercialization strategy.
Join us on June 4th for our Innovation Showcase where these founders will present to an audience of investors and collaboration partners. Learn more here!
Inapill is a seed-stage biotechnology company developing 1st-in-class small molecule therapeutics targeting immune cell metabolism (immunometabolism) for improved treatment of inflammatory and autoimmune diseases.
Greg Timblin, PhD
Email: [email protected]
We are developing a novel gene insertion platform to cure complex diseases at their genetic roots.
Sourab Kulkarni
Email: [email protected]
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer.
Andrew Bartynski, PhD
Email: [email protected]
Misogi Labs is building a platform for medicinal chemistry that improves speed, cost, and success rates of drug development through AI-driven molecular optimization.
Jessica Mustali
Email: [email protected]
We are a medical device company that is dedicated to revolutionizing diagnostic and therapeutic CT-guided needle placements.
Lohith Kini, MD, PhD
Email: [email protected]
Developing peptide-drug conjugates (PDCs) to exploit the distinct enzymatic properties of cancer cells.
Matt Smith, MBA
Email: [email protected]
Phaser Solutions is producing closed manifold fill/finish equipment.
Adam Morgenthaler
Email: [email protected]
ResVita Bio is a therapeutics company dedicated to developing life-changing treatments for skin diseases.
Amin Zargar, MS, PhD
Email: [email protected]
Pioneering immune shields for organ transplants.
Sheena McGowan, PhD
Email: [email protected]
Simurx, Inc. is a biotechnology company developing next-generation CAR T-cell therapies to overcome challenges in the tumor microenvironment (TME). By leveraging innovative protein engineering, Simurx enhances T-cell persistence, infiltration, and efficacy in solid tumors.
Shahab Asgharzadeh, MD
Email: [email protected]
Takeoff41 leverages AI to help newborns reach their highest level of health, starting with establishing a data-driven platform for total parenteral nutrition (TPN) prescriptions in neonatal intensive care units.
Joe Phongpreecha, PhD
Email: [email protected]
Our spatial biology platform develops novel therapeutics to manipulate immune cell interactions driving resistance to immunotherapy.
Assaf Magen, PhD
Email: [email protected]